Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01150474
Other study ID # 09-008045
Secondary ID
Status Completed
Phase Phase 4
First received June 23, 2010
Last updated December 23, 2014
Start date January 2011
Est. completion date December 2013

Study information

Verified date December 2014
Source Mayo Clinic
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

Our primary aim is to determine whether the routine use of belladonna and morphine suppositories will improve pain control following vaginal surgery. Treatment will begin immediately following surgery and every 8 hours for 16 hours.


Description:

Minimizing postoperative pain is vital to a successful surgical recovery. Inadequate pain control may result in nausea, vomiting, an extended hospital stay, and reduced patient satisfaction. Oral and parenteral narcotics are commonly used for pain relief and their use may exacerbate the incidence of sedation, nausea, and vomiting; ultimately delaying convalescence. Previous studies have demonstrated that rectal analgesia following surgery results in lower pain scores and less intravenous morphine consumption. Belladonna and opium suppositories are routinely prescribed at our institution and their efficacy has not been confirmed.

A prospective, randomized, double-blind, placebo-controlled trial will be undertaken using belladonna and opium rectal suppositories following vaginal surgery. Treatment will begin immediately following surgery and continue every 8 hours for a total of 3 doses.


Recruitment information / eligibility

Status Completed
Enrollment 103
Est. completion date December 2013
Est. primary completion date December 2013
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Scheduled for elective vaginal surgery requiring general anesthesia at the Mayo Clinic Hospital. This would include a vaginal hysterectomy with culdoplasty or post-hysterectomy prolapse repair, including culdoplasty with or without anterior/posterior repair.

Exclusion Criteria:

- Participation in another trial using an investigational product.

- Pregnancy.

- Scheduled for a non-vaginal surgical procedure.

- Scheduled for a robotic hysterectomy.

- Scheduled to have combined surgeries (vaginal surgery plus another non-vaginal surgery).

- There is a known hypersensitivity to belladonna and/or opium.

- Contraindication to narcotic use.

- Chronic pain with preoperative pain score greater than 4 out of 10 points.

- Clinically significant substance abuse.

- Mental condition that may impair the ability to provide study assessments.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Belladonna and Opium Suppositories
Belladonna (16.2 mg) and opium (60 mg) suppositories administered rectally immediately following surgery and every 8 hours for 16 hours for a total of 3 doses.
Placebo Suppositories
Placebo suppositories administered rectally immediately following surgery and every 8 hours for 16 hours for a total of 3 doses.

Locations

Country Name City State
United States Mayo Clinic Phoenix Arizona

Sponsors (1)

Lead Sponsor Collaborator
Kristina A. Butler

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pain at Hour 4 Pain at 4 hours was recorded using a linear analog pain scale, with 0 being "no pain," and 10 being "worst pain imaginable." 4 hours following surgery No
Secondary Pain at Hour 12 Pain at 12 hours was recorded using a linear analog pain scale, with 0 being "no pain," and 10 being "worst pain imaginable." 12 hours after surgery. No
Secondary Pain at Hour 20 Pain at 20 hours was recorded using a linear analog pain scale, with 0 being "no pain," and 10 being "worst pain imaginable." 20 hours after surgery. No
Secondary Narcotic Rescue Medication Use of all ancillary narcotic medications was taken from the medical record. For 24 hours following surgery No
Secondary Number of Subjects With Nausea This information was taken from the medical record. Approximately 12 hours after surgery No
Secondary Number of Subjects With Vomiting This information was taken from the medical record. Within 20 hours of surgery No
Secondary Number of Times Antiemetic Rescue Medication Was Used First 24 hours after surgery No
Secondary Number of Subjects Who Used Antiemetic Rescue Medications First 24 hours after surgery No
Secondary Satisfaction With Pain Relief Patient satisfaction with pain relief was evaluated 24 hours after surgery using a linear analog satisfaction scale, with 0 being "very dissatisfied," and 10 being "very satisfied." Approximately 24 hours following surgery No
See also
  Status Clinical Trial Phase
Completed NCT03446950 - Study Investigating Role of Unalike Patient Positioning on PROMIS Scores N/A
Completed NCT03573557 - Improved Intra-operative Safety From Optimal Selection of Anti-slip Surface N/A
Suspended NCT03854370 - Vaginal Prep Solutions to Reduce Bacteria Colony Counts in Patients Having a Vaginal Surgery N/A